Skip to main content

Table 1 Demographic data and clinical characteristics of the study group

From: Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus

Demographic data and clinical characteristics
Age (years)
 Mean ± SD 51.400 ± 12.838
 Range (23–77)
Gender (N (%))
 Male 25 (50%)
 Female 25 (50%)
Co-morbidities (N (%))
 DM 13 (26%)
 HTN 28 (56%)
 ISHD 4 (8%)
 Others 2 (4%)
Child score calculation (N (%))
 A5 42 (84%)
 A6 8 (16%)
Liver by PAUS (N (%))
 Normal hepatic echopattern 22 (44%)
 Chronic parenchymatous liver disease 17 (34%)
 Coarse echopattern 11 (22%)
Spleen by PAUS
 Enlarged 7 (14%)
 Normal 43 (86%)
Ascites by PAUS
 Yes 2 (4%)
 No 48 (96%)
Baseline laboratory investigations (week 0), mean ± SD (range)
Alpha feto protein (IU/l) 3.459 ± 3.948 (0.54–26)
Serum Creatinine (mg/dl) 7.345 ± 1.981 (3.6–12.75)
PCR for HCV (IU/ml) week 0 2,629,176.880 ± 4,598,628.996 (10,601–23,102,362)
  1. DM diabetes mellitus, HTN hypertension, ISHD ischemic heart disease, PCR polymerase chain reaction, HCV hepatitis C virus, PAUS pelvi-abdominal ultrasound